Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

• DOI: 10.1016/j.cmet.2016.09.013
• Publication Date: 2016-10-27T16:16:49Z
• Authors: Kathryn F. Mills; Shohei Yoshida; Liana R. Stein; Alessia Grozio; Shunsuke Kubota; Yo Sasaki; Philip Redpath; Marie E. Migaud; Rajendra S. Apte; Koji Uchida; Jun Yoshino; Shin-ichiro Imai
• Keywords: Nicotinamide mononucleotide; Nicotinamide phosphoribosyltransferase

Highlights•NMN suppresses age-associated body weight gain and enhances energy metabolism•NMN improves insulin sensitivity, eye function, other features with no toxicity•NMN prevents gene expression changes in a tissue-specific manner•NMN is an effective anti-aging intervention that could be translated to humansSummaryNAD+ availability decreases age certain disease conditions. Nicotinamide mononucleotide (NMN), key NAD+ intermediate, has been shown enhance biosynthesis ameliorate various pathologies mouse models. In this study, we conducted 12-month-long NMN administration regular chow-fed wild-type C57BL/6N mice during their normal aging. Orally administered was quickly utilized synthesize tissues. Remarkably, effectively mitigates physiological decline mice. Without any obvious toxicity or deleterious effects, suppressed gain, enhanced metabolism, promoted physical activity, improved sensitivity plasma lipid profile, ameliorated function pathophysiologies. Consistent these phenotypes, prevented metabolic organs mitochondrial oxidative metabolism mitonuclear protein imbalance skeletal muscle. These effects of highlight the preventive therapeutic potential intermediates as interventions humans.Graphical abstract